Albert Labs International Corp.

CNSX:ABRT Stock Report

Market Cap: CA$372.1k

Albert Labs International Valuation

Is ABRT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ABRT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ABRT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ABRT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABRT?

Key metric: As ABRT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ABRT. This is calculated by dividing ABRT's market cap by their current book value.
What is ABRT's PB Ratio?
PB Ratio-0.8x
Book-CA$443.07k
Market CapCA$372.07k

Price to Book Ratio vs Peers

How does ABRT's PB Ratio compare to its peers?

The above table shows the PB ratio for ABRT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average16.1x
CURE.X Biocure Technology
0.2xn/aCA$313.3k
NAV NAVCO Pharmaceuticals
57.4xn/aCA$1.1m
ENBI Entheon Biomedical
5xn/aCA$1.2m
VXL Vaxil Bio
1.7xn/aCA$1.4m
ABRT Albert Labs International
n/an/aCA$372.1k

Price-To-Book vs Peers: ABRT has negative equity and a Price-To-Book Ratio (-0.8x) compared to the peer average (1.8x).

Price to Book Ratio vs Industry

How does ABRT's PB Ratio compare vs other companies in the CA Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
QPT Quest PharmaTech
0.3xn/aUS$4.24m
CURE.X Biocure Technology
0.2xn/aUS$224.17k
No more companies available in this PB range
ABRT is unprofitableIndustry Avg. 2.8xNo. of Companies2PB01.22.43.64.86+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ABRT has negative equity and a Price-To-Book Ratio (-0.8x) compared to the Canadian Biotechs industry average (1.2x).

Price to Book Ratio vs Fair Ratio

What is ABRT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABRT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-0.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ABRT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.02

7D

-14.8%

1Y

-65.2%

Fennec Pharmaceuticals

US$145.9m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

7D

30.1%

1Y

-38.9%

Medexus Pharmaceuticals

CA$60.4m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.45

7D

15.6%

1Y

61.2%